Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright

Aligos Therapeutics (NASDAQ:ALGS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $75.00 price target on the stock.

Aligos Therapeutics Trading Down 28.1 %

Shares of NASDAQ ALGS opened at $10.18 on Friday. The firm has a market capitalization of $795.16 million, a PE ratio of -7.95 and a beta of 2.18. The firm’s 50-day moving average is $13.26 and its 200-day moving average is $16.41. Aligos Therapeutics has a 1 year low of $8.70 and a 1 year high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The company had revenue of $1.06 million for the quarter. During the same period in the prior year, the business earned ($10.75) earnings per share. As a group, equities research analysts anticipate that Aligos Therapeutics will post -8.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC boosted its position in Aligos Therapeutics by 17.6% during the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after acquiring an additional 98,628 shares during the last quarter. Opaleye Management Inc. acquired a new position in Aligos Therapeutics during the fourth quarter worth $861,000. Altitude Crest Partners Inc. bought a new position in Aligos Therapeutics in the fourth quarter valued at $1,889,000. Finally, Armistice Capital LLC bought a new stake in Aligos Therapeutics during the 4th quarter worth about $4,538,000. 60.43% of the stock is owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).